Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 318 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Citalopram Clear all
Active, not recruiting Phase 3 Interventional

Escitalopram for Agitation in Alzheimer's Disease

NCT03108846
View directory record Official record
Conditions
Dementia
Interventions
Escitalopram, Placebo
Drug
Lead sponsor
JHSPH Center for Clinical Trials
Other
Eligibility
18 Years to 109 Years
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
22
States / cities
Sun City, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 17, 2026, 5:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Psychopharmacology of Fear-Potentiated Startle in Humans

NCT00044096
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 45 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Results available

Combination Treatment Study for Memory Impairment and Depression

NCT01658228
View directory record Official record
Conditions
Depression, Mild Cognitive Impairment
Interventions
Donepezil, Placebo, Citalopram, Venlafaxine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 17, 2026, 5:16 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

p11 Protein Levels in Patients With Major Depressive Disorder Treated With Citalopram

NCT00697268
View directory record Official record
Conditions
Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 3 Interventional

Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder

NCT00329446
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Quetiapine Fumarate, Escitalopram oxylate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2009 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Danoprevir/Ritonavir on the Pharmacokinetics of Escitalopram and S-Demethylcitalopram in Healthy Volunteers

NCT01418274
View directory record Official record
Conditions
Healthy Volunteer
Interventions
danoprevir, escitalopram, ritonavir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 17, 2026, 5:16 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)

NCT01111565
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
Escitalopram, Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Tucson, Arizona • Chino, California • Riverside, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Oct 17, 2026, 5:16 AM EDT
Recruiting Phase 2 Interventional

A Study Utilizing Escitalopram in Glioma Patients

NCT03728673
View directory record Official record
Conditions
Glioma of Brain, Glioma
Interventions
Escitalopram Oral Capsules
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional Results available

Citalopram to Enhance Cognition in HD

NCT00271596
View directory record Official record
Conditions
Huntington Disease, Chorea, Executive Dysfunction
Interventions
20mg daily citalopram, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Scottsdale, Arizona • Iowa City, Iowa • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Oct 17, 2026, 5:16 AM EDT
Terminated Not applicable Interventional Results available

Study of Repetitive Transcranial Magnetic Stimulation (rTMS) as Adjuvant Treatment for Depression

NCT01115699
View directory record Official record
Conditions
Depression
Interventions
Repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 13, 2013 · Synced Oct 17, 2026, 5:16 AM EDT
Terminated Not applicable Interventional

Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia

NCT01420575
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Visual Decision Aid and Shared Decision Making Model, Usual Care
Behavioral
Lead sponsor
VA Nebraska Western Iowa Health Care System
Federal
Eligibility
19 Years to 65 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)

NCT01312922
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
PNB01 fixed dose combination of pipamperone and citalopram, Citalopram, Pipamperone
Drug
Lead sponsor
PharmaNeuroBoost N.V.
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
26
States / cities
Glendale, California • National City, California • Riverside, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 17, 2026, 5:16 AM EDT
Terminated Not applicable Interventional Results available

Ramelteon for Sleep Initiation Insomnia in Individuals With Panic Disorder Who Are Also on Escitalopram for Anxiety

NCT00746239
View directory record Official record
Conditions
Panic Disorder, Insomnia
Interventions
Placebo and Escitalopram, Ramelteon and Escitalopram
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 2Phase 3 Interventional Results available

SAM-e for the Treatment of Depression in Patients With Parkinson's Disease

NCT00070941
View directory record Official record
Conditions
Parkinson's Disease, Depression
Interventions
SAM-e, oral escitalopram, placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
30 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Obsessive Compulsive Disorder in Children

NCT00074815
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Serotonin reuptake inhibitors management, Cognitive behavioral therapy by a psychologist, Instructional cognitive behavioral therapy by a psychiatrist
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
7 Years to 17 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
3
States / cities
Durham, North Carolina • Philadelphia, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT01838681
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Placebo, Brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
8
States / cities
Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Fixed Doses of BMS 820836 in the Treatment of Patients With Treatment Resistant Major Depression

NCT01369095
View directory record Official record
Conditions
Depression
Interventions
Duloxetine, Escitalopram, BMS-820836 Placebo, BMS-820836
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
48
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Chino, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 17, 2026, 5:16 AM EDT
Terminated No phase listed Observational

Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder

NCT01598324
View directory record Official record
Conditions
Treatment-Resistant Depression
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2013 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 4 Interventional

Escitalopram Treatment of Patients With Agitated Dementia

NCT00260624
View directory record Official record
Conditions
Alzheimer's Disease, Psychomotor Agitation
Interventions
Escitalopram (Lexapro)
Drug
Lead sponsor
University of Rochester
Other
Eligibility
61 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
3
States / cities
Fairport, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 24, 2012 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effects of Duloxetine on Norepinephrine

NCT00414323
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Duloxetine, Escitalopram, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Glendale, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2007 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 4 Interventional

Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy

NCT00595699
View directory record Official record
Conditions
Major Depression, Temporal Lobe Epilepsy
Interventions
escitalopram, placebo
Drug
Lead sponsor
Conrad, Erich J., M.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 18, 2011 · Synced Oct 17, 2026, 5:16 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Escitalopram Effects on CSF Amyloid Beta

NCT02161458
View directory record Official record
Conditions
Amyloid Beta Protein
Interventions
Escitalopram 20mg for 2 weeks, Escitalopram 20mg for 8 weeks, Escitalopram 30mg for 8 weeks, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
60 Years to 85 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
2
States / cities
St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 17, 2026, 5:16 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

International Study to Predict Optimised Treatment - in Depression

NCT00693849
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Escitalopram, Sertraline, Venlafaxine-XR
Drug
Lead sponsor
BRC Operations Pty. Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,688 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2019
U.S. locations
13
States / cities
Colton, California • Mission Viejo, California • Stanford, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 17, 2026, 5:16 AM EDT